CO2022017261A2 - Anticuerpos biespecíficos para linfocitos t activados por proteasa - Google Patents

Anticuerpos biespecíficos para linfocitos t activados por proteasa

Info

Publication number
CO2022017261A2
CO2022017261A2 CONC2022/0017261A CO2022017261A CO2022017261A2 CO 2022017261 A2 CO2022017261 A2 CO 2022017261A2 CO 2022017261 A CO2022017261 A CO 2022017261A CO 2022017261 A2 CO2022017261 A2 CO 2022017261A2
Authority
CO
Colombia
Prior art keywords
protease
idiotype
bispecific
cell activating
specific polypeptides
Prior art date
Application number
CONC2022/0017261A
Other languages
English (en)
Inventor
Peter Bruenker
Ekkehard Moessner
Thomas Hofer
Christian Klein
Anne Freimoser-Grundschober
Gutierrez Cirlos Alejandro Carpy
Christiane Neumann
Martina Geiger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2022017261A2 publication Critical patent/CO2022017261A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

La presente invención se refiere en general a nuevas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo. La presente invención también se refiere a polinucleótidos que codifican dichas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo, y vectores y células huésped que comprenden dichos polinucleótidos. La invención se refiere además a procedimientos para producir las moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo de la invención, y a procedimientos de uso de estas moléculas biespecíficas activadoras de linfocitos T activables por proteasa y polipéptidos específicos de idiotipo en el tratamiento de una enfermedad.
CONC2022/0017261A 2020-06-19 2022-11-30 Anticuerpos biespecíficos para linfocitos t activados por proteasa CO2022017261A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181072 2020-06-19
PCT/EP2021/066335 WO2021255137A1 (en) 2020-06-19 2021-06-17 Protease-activated t cell bispecific antibodies

Publications (1)

Publication Number Publication Date
CO2022017261A2 true CO2022017261A2 (es) 2023-02-27

Family

ID=71111324

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0017261A CO2022017261A2 (es) 2020-06-19 2022-11-30 Anticuerpos biespecíficos para linfocitos t activados por proteasa

Country Status (17)

Country Link
US (1) US20230287145A1 (es)
EP (1) EP4168444A1 (es)
JP (1) JP2023529982A (es)
KR (1) KR20230025667A (es)
CN (1) CN115698080A (es)
AR (1) AR122659A1 (es)
AU (1) AU2021291002A1 (es)
BR (1) BR112022024469A2 (es)
CA (1) CA3177239A1 (es)
CL (1) CL2022003522A1 (es)
CO (1) CO2022017261A2 (es)
CR (1) CR20220604A (es)
IL (1) IL296429A (es)
MX (1) MX2022015890A (es)
PE (1) PE20231552A1 (es)
TW (1) TW202214704A (es)
WO (1) WO2021255137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202402794A (zh) * 2022-03-28 2024-01-16 瑞士商赫孚孟拉羅股份公司 經改良的ｆｏｌｒ１蛋白酶可活化之ｔ細胞雙特異性抗體
WO2024040127A2 (en) * 2022-08-16 2024-02-22 Northwestern University Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma
WO2024068572A1 (en) * 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MY192312A (en) 2013-02-26 2022-08-17 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN114891102A (zh) 2015-10-29 2022-08-12 豪夫迈·罗氏有限公司 抗变体Fc区抗体及使用方法
FI3433280T3 (fi) * 2016-03-22 2023-06-06 Hoffmann La Roche Proteaasin aktivoimia t-solubispesifisiä molekyylejä
SG11201808085WA (en) * 2016-03-22 2018-10-30 Hoffmann La Roche Protease-activated t cell bispecific molecules
WO2018108759A1 (en) * 2016-12-13 2018-06-21 F. Hoffmann-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
TWI829831B (zh) * 2018-12-21 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體

Also Published As

Publication number Publication date
KR20230025667A (ko) 2023-02-22
CN115698080A (zh) 2023-02-03
JP2023529982A (ja) 2023-07-12
CA3177239A1 (en) 2021-12-23
AU2021291002A1 (en) 2022-10-13
US20230287145A1 (en) 2023-09-14
BR112022024469A2 (pt) 2023-01-17
MX2022015890A (es) 2023-01-24
CR20220604A (es) 2023-01-23
EP4168444A1 (en) 2023-04-26
AR122659A1 (es) 2022-09-28
TW202214704A (zh) 2022-04-16
IL296429A (en) 2022-11-01
CL2022003522A1 (es) 2023-07-21
WO2021255137A1 (en) 2021-12-23
PE20231552A1 (es) 2023-10-03

Similar Documents

Publication Publication Date Title
CL2022003522A1 (es) Anticuerpos biespecíficos para linfocitos t activados por proteasa
AR120543A2 (es) Moléculas biespecíficas de células t activadas por proteasas
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
DOP2023000165A (es) Anticuerpos de unión a cd3
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
UY37829A (es) Muteínas de interleucina 21 y métodos de tratamiento
PH12018502035A1 (en) Protease-activated t cell bispecific molecules
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
CO2017003048A2 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1)
AR095541A1 (es) Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
CL2012002329A1 (es) Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08)
AR092050A1 (es) Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
DE60336228D1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
AR122658A1 (es) Anticuerpos que se unen a cd3
PE20171336A1 (es) Anticuerpos contra tau y sus usos
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
AR108552A1 (es) Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana